featured
Preclinical and Clinical Evaluation of the LRRK2 Inhibitor DNL201 for PD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Science Translational Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease
Sci Transl Med 2022 Jun 08;14(648)eabj2658, D Jennings, S Huntwork-Rodriguez, AG Henry, JC Sasaki, R Meisner, D Diaz, H Solanoy, X Wang, E Negrou, VV Bondar, R Ghosh, MT Maloney, NE Propson, Y Zhu, RD Maciuca, L Harris, A Kay, P LeWitt, TA King, D Kern, A Ellenbogen, I Goodman, A Siderowf, J Aldred, O Omidvar, ST Masoud, SS Davis, A Arguello, AA Estrada, J de Vicente, ZK Sweeney, G Astarita, MT Borin, BK Wong, H Wong, H Nguyen, K Scearce-Levie, C Ho, MD TroyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.